Lardә Najeriyabe lan, kansa kansabe kuli kwasuwabe kammabowo kuru shima kwasuwa kammabo do zauro kamma suwudin ma wo, adәye sәkkә kammabo do suro kamma 100,000 son tuwandinna 32.8 yeyi-a kuru sandi kammabo do 16.3 yeyi-a suwudin.
Adә shima kәrmu doni yala Americayen kozәnama wo.
Kwasa dǝga dareram lan notǝ dǝ, kareya kulastaye ngǝwu gǝnyi, kuru bayan kǝla kwasa dǝben fulutǝ dǝ shima adǝma dalil nǝm kǝrmu Nigeriabe dǝro.
United Stateslan, kwasa kansabe prostatebe shima kwasa kansabe kən indimi do nu'nguwuna wo suro kongayen, saa woson kongawa 40,000 karingabe kwasa shima dən sasanbin.
Kǝrmu donyi prostatebe dǝ gana gana fulujin ngawo saa 1990 lan, amma kwasa shima dǝ kǝla lamar nǝlewabe ro zauro zǝkǝna.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Kәlanzәma ro cistәgә: liita']
['Websayit adә ilmu matәbe-a bayan matәbe bas nankaro cedo kuru shawari liyitabe au cidawa cidawu liyitabe diobe gәnyi.']
['Bayanwa yitagattәgәna so dә kwasa laa au kwasa laa asutu au kurun dio ro faidatәmba, kuru am doni shawaria liyitaye mazayin so dә dokta lasisatәna ro manatә saadin.']
['Martәne netәram kәrәnbe do korowa dә ro jawawu suwudin dә, taganasmaro kalkal gәnyi sa lamba isәna dәn. Misallo, nәm nguwu am doni kwasa laa taganasbe shiro asuzana ma.']
["Sambi so ro shawari kam litari nәm au kam gade nasha nәlewabe nozәna ma ye la'atar ro matәne. Shawari kam litaribe nozәna ma ro tәmmaro hangal gәnyi gәnane au sha matә lan loktu gozәnyi awo laa website adәn kәrәnәmma yen. Nyiye kurun nәlewabe batәrammin maa, talfon 911 lan buwoze au njim liwalabe karungu ma ro lenәme. Alaka nәlewa-a dondibe ba ma tuwandin web site adә men au shilan faidatәmen. BioMedLib-a cidawunzә-a, au kam do web site adә ro banazәyin-aye, affima bayanzәna au manazәna ma sadimba, bayanwa suro adәben tuwandin au shilan faidatәmen."]
['Suro nәm kәla nәm ngәla yen awo laa au kare laa kәla intanetndeyen au cidawandeyen mbejiye hakku nәm kakkadi ruotәbe nyiro kalzәna ma ye mbeji maa, nyi (au wakkilnәm) andero watiya zuwune awo au kare dә tutuluwu, au na dәro nazәgә dә tutuluwu.']
["Zande so dә ruwo lan zuzaiya, email men (adәretәm emailye dә nasha 'Lam'atarro manәmin)"]
['DMCA ye məradənzə bayan kəla nzətkawo kərmaabedəbe bayanwa anyi surodən mbejiro: (1) bayan kəla cida nzətkawobe dunonzə dunonzə kaltəgəbe dunonzə kaltəgəbe; (2) bayan kəla awoa zortəbe dunonzə kaltəgəbe dunonzə kuru bayan kəzəkə andeya səkə awoadəga fandəmin; (3) bayan kəlanəm lamba fantəbe, suro nzəranəm-a, lamba telehonbe-a kuru email-be-a; (4) bayan kəlanəmbe kəla nyiye tawatkənənde kəla awoa zortəbe dunonzə kaltəgəbe dunonzəye dunonzəye səkə au wakilinzəye, au shara laabe səkə; ']
['(5) bayan nyima, kalima jirebero, ruwotәgәna, bayan suro watiyade dә kalkalzәna kuru nyiye hakku kәlanzәbe hakkuwa ləbtәma soye warmatәgәbe dәga nonәmma;']
['kuru (6) mukko dunowa au lantarkibe hakkiwa ləbtamabe au kam laaye wakil zəben cida sədənabe. ']
['Bayanna samibe samma kәltәgә nyiye mowonzә zәktә lamar buruwunәmye gәrәmin.']
['Lǝtǝram']
['Martәne ande ro watiya emailye lan koro/shawari laa manane.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
